Paper Details

  1. Home
  2. Paper Details

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.

Author: BellatiFilippo, BraicuElena Ioana, CasertaDonatella, CostanziFlavia, De MarcoMaria Paola, DorigoOliver, GasparriMaria Luisa, MirzaMansoor Raza, NutiMarianna, PignataSandro, Ray-CoquardIsabelle, RuscitoIlary, SehouliJalid, du BoisAndreas

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

PARP inhibitors are a new class of targeted agents that are effective and safe for the treatment of recurrent and primary advanced ovarian cancer.
Paper Details　
Original Abstract of the Article :
The second decade of 2000s is witnessing a new ovarian cancer (OC) paradigm shift thanks to the results recently obtained by a new class of targeted agents: the Poly(ADP-ribose)polymerase (PARP)-Inhibitors (PARPi). Aim of this meta-analysis is to analyze available results obtained with PARPi, admini...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ctrv.2020.102040

データ提供：米国国立医学図書館（NLM）

PARP Inhibitors: A New Hope in the Fight Against Ovarian Cancer

The battle against ovarian cancer is an ongoing journey, and researchers are constantly seeking new weapons to fight this formidable foe. This research examines the potential of PARP inhibitors, a new class of targeted agents, in the treatment of primary and recurrent ovarian cancer. Researchers conducted a meta-analysis of 12 phase II/III randomized controlled trials to evaluate the efficacy and safety of PARP inhibitors in various treatment settings. The analysis suggests that PARP inhibitors, administered alone or in combination with other therapies, show promising results in treating recurrent and primary advanced ovarian cancer. These findings offer hope for patients with this challenging disease.

Promising Results for Ovarian Cancer Treatment

This meta-analysis provides encouraging evidence for the potential of PARP inhibitors in the treatment of ovarian cancer. The observed efficacy and safety profile suggest that this new class of targeted agents could significantly benefit patients with recurrent and primary advanced disease.

Hope for Ovarian Cancer Patients

Ovarian cancer is a complex and challenging disease, but research continues to offer new avenues for treatment. This research highlights the potential of PARP inhibitors to improve outcomes for patients, offering hope for a brighter future in the fight against this devastating disease.

Dr.Camel's Conclusion

The fight against ovarian cancer is a journey through a vast and unforgiving desert. This research highlights the potential of PARP inhibitors to provide a much-needed oasis of hope for patients, offering new treatment options and potentially improving outcomes.

Date :
  1. Date Completed 2020-06-24
  2. Date Revised 2020-06-24
Further Info :

Pubmed ID

32485510

DOI: Digital Object Identifier

10.1016/j.ctrv.2020.102040

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.